Dynamic contrast enhanced ultrasound assessment of the vascular effects of novel therapeutics in early stage trials

European Radiology

Volumn 22, Issue 7, 2012, Pages 1442-1450

  Leen, Edward ^a   Averkiou, Michalakis ^b   Arditi, Marcel ^c   Burns, Peter ^d   Bokor, Daniela ^e   Gauthier, Thomas ^a,f   Kono, Yuko ^g   Lucidarme, Olivier ^h  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CYPRUS   (Cyprus)

^c Bracco Suisse SA   (Switzerland)

^d UNIVERSITY OF TORONTO   (Canada)

^e Bracco Imaging SpA   (Italy)

^f PHILIPS HEALTHCARE   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Contrast agents; Perfusion quantification; Therapy response assessment; Ultrasonography; Vascular targeted therapy

Indexed keywords

CONTRAST MEDIUM;

ARTICLE; CLINICAL STUDY; CONTRAST ENHANCEMENT; DYNAMIC CONTRAST ENHANCED ULTRASOUND; HUMAN; PRIORITY JOURNAL; ULTRASOUND; VASCULAR TUMOR;

CLINICAL TRIALS AS TOPIC; CONTRAST MEDIA; EUROPE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NORTH AMERICA; PRACTICE GUIDELINES AS TOPIC; REFERENCE STANDARDS; ULTRASONOGRAPHY;

EID: 84864645139     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-011-2373-2     Document Type: Article

References (27)

1. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974
2. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286
3. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739
4. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
5. Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759
6. Nathan PD, Vinayan A, Stott D et al (2010) CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 9:15-19
7. Rini BI, Atkins MB (2009) Resistance to targeted therapy in renalcell carcinoma. Lancet Oncol 10:992-1000
8. Levashova Z, Backer M, Hamby CVet al (2010) Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-Treated murine mammary tumors. J Nucl Med 51:959-966
9. Hahn OM, Yang C, Medved M et al (2008) Dynamic contrastenhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26:4572-4578
10. Wilson SR, Burns PN (2010) Microbubble-enhanced US in body imaging: what role? Radiology 257:24-39
11. Quaia E (2011) The real capabilities of contrast-enhanced ultrasound in the characterization of solid focal lesions. Eur Radiol 21 (3):457-462
12. Quaia E (2011) Assessment of tissue perfusion by contrastenhanced ultrasound. Eur Radiol 21:604-615
13. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S (1998) Quantification of myocardial blood flow with ultrasoundinduced destruction of microbubbles administered as a constant venous infusion. Circulation 97:473-483
14. Krix M, Kiessling F, Vosseler S, Farhan N, Mueller MM, Bohlen P, Fusenig NE, Delorme S (2003) Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography. Cancer Res 63:8264-8270
15. Arditi M, Frinking PJA, Zhou X et al (2006) A new formalism for the quantification of tissue perfusion by the destructionreplenishment method in contrast ultrasound imaging. IEEE Trans Ultrason Ferroelectr Freq Control 53:1118-1129
16. Palmowski M, Lederle W, Gaetjens J, Socher M, Hauff P, Bzyl J, Semmler W, Günther RW, Kiessling F (2010) Comparison of conventional time-intensity curves vs. maximum intensity over time for post-processing of dynamic contrast-enhanced ultrasound. Eur J Radiol 75:e149-e153
17. Hudson JM, Karshafian R, Burns PN (2009) Quantification of flow using ultrasound and microbubbles: a disruption replenishment model based on physical principles. Ultrasound Med Biol 35:2007-2020
18. Averkiou M, Lampaskis M, Kyriakopoulou K et al (2010) Quantification of tumor microvascularity with respiratory gated contrast enhanced ultrasound for monitoring therapy. Ultrasound Med Biol 36:68-77
19. Williams R, Hudson JM, Lloyd B et al (2011) Dynamic microbubble contrast-enhanced ultrasound (DCE ultrasound) to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. Radiology 260:581-590
20. Strouthos C, Lampaskis M, Sboros Vet al (2010) Indicator dilution models for the quantification of microvascular blood flow with bolus administration of ultrasound contrast agents. IEEE Trans Ultrason Ferroelectr Freq Control 57:1296-1310
21. Bertolotto M, Pozzato G, Croce LS et al (2006) Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results. Invest Radiol 41:15-21
22. De Giorgi U, Aliberti C, Benea G et al (2005) Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 11:6171-6176
23. Lamuraglia M, Escudier B, Chami L et al (2006) To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrastenhanced Doppler ultrasound. Eur J Cancer 42:2472-2479
24. Lassau N, Koscielny S, Albiges L et al (2010) Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 16:1216-1225
25. Lassau N, Koscielny S, Chami L et al (2011) Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification -preliminary results. Radiology 258:291-300
26. Lassau N, Lamuraglia M, Chami L et al (2006) Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 187:1267-1273
27. Caproni N, Marchisio F, Pecchi A, Canossi B, Battista R, D'Alimonte P, Torricelli P (2010) Contrast-enhanced ultrasound in the characterisation of breast masses: utility of quantitative analysis in comparison with MRI. Eur Radiol 20(6):1384-1395